Back to results
US 2024/0366972 A1Published application
Chimeric Antigen Receptor-Modified NK-92 Cells
AssigneeImmunityBio, Inc.
InventorsLaurent H. Boissel, Hans G. Klingemann
Life of this patent
Estimating the term…
Abstract
Provided are NK-92 cells expressing a chimeric antigen receptor (CAR). The CAR can comprise an intracellular domain of FcεRIγ. Also described are methods for treating a patient having or suspected of having a disease that is treatable with NK-92 cells, such as cancer or a viral infection, comprising administering to the patient NK-92-CAR cells.
Claims20
A genetically modified NK cell carrying a non-viral vector encoding a membrane bound recombinant chimeric antigen receptor (CAR),
- wherein the CAR comprises in a single polypeptide chain:
- an extracellular anti-EGFR scFv domain according to SEQ ID NO:32,
- a hinge domain,
- a transmembrane domain, and
- a FcεRIγ signaling domain according to SEQ ID NO:1;
- and
- wherein the NK cell is an NK-92 cell.
4 more elements
A genetically modified NK cell, comprising:
- a recombinant nucleic acid encoding a chimeric antigen receptor (CAR), wherein the recombinant nucleic acid is a transfected plasmid;
- wherein the NK cell is an NK-92 cell;
- wherein the CAR comprises in a single polypeptide chain an extracellular anti-EGFR scFv domain according to SEQ ID NO:32, a hinge domain, a transmembrane domain, and a FcεRIγ signaling domain according to SEQ ID NO:1.
Dependencies are inferred from the claim text.